Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
3,515.00
-200.00 (-5.38%)
Nov 20, 2026, 3:30 PM KST
Vaxcell-Bio Therapeutics Revenue
In the year 2024, Vaxcell-Bio Therapeutics had annual revenue of 1.90B KRW with 13,737.28% growth. Vaxcell-Bio Therapeutics had revenue of 921.53M in the quarter ending December 31, 2024, with 6,615.06% growth. That makes Vaxcell-Bio Therapeutics the 43,071st largest company in the world by revenue and 2,583rd in South Korea.
Revenue
1.90B
Revenue Growth
+13,737.28%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
81.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 1.89B | 13,737.28% |
| Dec 31, 2023 | 13.72M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| Amicogen | 48.08B |
| Prestige BioPharma | 26.07B |
| Anterogen.Co.,Ltd. | 9.29B |
| GeneOne Life Science | 9.07B |
| NeoImmuneTech | 6.60B |
| Genexine | 5.81B |